| Autor: |
Miakova NV; Research Institute of Pediatric Hematology and Oncology, Ministry of Health of the RF, Russian Children's Clinical Hospital, Moscow., Hartmann R, Rudneva AE, Trubina NM, Fechina LG, Timakov AM, Shamardina AV, Lebedev VV, Varfolomeeva SR, Dudkin SD, Dyshlevaia ZM, Timofeeva VN, Rumiantsev AG, Henze H, Karachunskiĭ AI |
| Jazyk: |
ruština |
| Zdroj: |
Voprosy onkologii [Vopr Onkol] 2002; Vol. 48 (3), pp. 340-6. |
| Abstrakt: |
The report deals with the results of application of an original protocol--the Berlin-Moscow-91 (BM-91)--for the treatment of acute lymphoblastic leukemia (ALL) in children. The researchers' major concern was to improve survival and cut down side-effects incidence as well as to prevent and successfully manage occult neuroleukemia as a potential source of relapse. Patients aged 5 months-15 years received the BM-91 and ALL BFM-90m treatment first at one clinic and later at several centers. Out of 852 children with primary diagnosis of ALL admitted to Russian hematological hospitals (March 2, 1991-November 3, 2000), 687 were included into the study; 329 received the MB-91 protocol. Nine-year recurrence-free survival was 73% while overall survival--80%. Toxic side-effects after L-asparaginase were reported in 27 (7.9%). It is concluded that good results in childhood ALL treatment can be achieved without resorting to high-dosage chemotherapy and radiation in most cases. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
